Robinhood reports August 2025 customer and trading metrics
Investing.com - Needham has reiterated a Buy rating and $121.00 price target on Boston Scientific (NYSE:BSX), currently trading at $105.23 with a market capitalization of $156 billion. The company, which maintains a "GREAT" financial health score according to InvestingPro, is seeing renewed analyst optimism following its recent acquisition of Bolt Medical.
Boston Scientific acquired the privately-held Bolt Medical on April 2, 2025, and plans to launch Bolt’s laser-based intravascular lithotripsy (IVL) system for peripheral use in late 2025, according to Needham.
The firm notes that enrollment began in Boston Scientific’s FRACTURE study for coronary use of the technology in July 2025, with the total addressable market for IVL estimated at approximately $8.5 billion based on data from Shockwave Medical (NYSE:JNJ).
Needham believes Boston Scientific’s existing Peripheral Interventions and Interventional Cardiology product portfolios and sales forces should enable rapid market share capture in the IVL segment, with the Bolt system reportedly offering improved deliverability, increased pulses, and more consistent targeted acoustic treatment compared to Shockwave Medical’s IVL system.
The firm estimates that IVL technology could add 0.3% to Boston Scientific’s revenue growth and 0.5% to EPS growth over the next five years, supporting its continued Buy recommendation. This aligns with the strong analyst consensus, though InvestingPro analysis suggests the stock is currently trading above its Fair Value. Investors can access detailed valuation metrics and 15 additional ProTips through InvestingPro’s comprehensive research report.
In other recent news, Elutia Inc. has entered into a definitive agreement to sell its EluPro and CanGaroo bioenvelopes to Boston Scientific for $88 million in cash. The transaction is expected to close in the fourth quarter of 2025, transferring ownership of these products to Boston Scientific. Meanwhile, Oppenheimer has upgraded Boston Scientific’s stock rating from Perform to Outperform, citing it as one of the best large-cap MedTech growth stories due to its disciplined mergers and acquisitions strategy and strong execution in the electrophysiology franchise. In executive news, Boston Scientific announced that Jeffrey B. Mirviss, Executive Vice President and President of Peripheral Interventions, will retire from his role effective December 1, 2025, but will remain as a senior advisor until February 27, 2026. Additionally, the FDA disclosed a potentially high-risk issue with Boston Scientific’s defibrillation leads, linked to patient deaths. The company has notified customers about the affected ENDOTAK RELIANCE Defibrillation leads, which may impact shock efficacy or require early replacement. These developments are part of ongoing efforts to enhance the Medical Device Recall Program.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.